|
Video: What is a Stock Split?
|
|
Amicus Therapeutics is a biotechnology company focused on discovering, developing, and delivering medicines for diseases. Co.'s gene therapy portfolio pipeline include Pompe disease, Fabry disease, CDKL5 deficiency disorder, ceroid lipofuscinosis, neuronal, Mucopolysaccharidosis Type IIIB, as well as a program in Mucopolysaccharidosis Type IIIA. Co.'s collaboration with University of Pennsylvania also provides Co. with disease-specific access and option rights to develop new gene therapy platform technologies and programs for most lysosomal disorders and a portfolio of other rare diseases. According to our Amicus Therapeutics stock split history records, Amicus Therapeutics has had 0 splits. | |
|
Amicus Therapeutics (FOLD) has 0 splits in our Amicus Therapeutics stock split history database.
Looking at the Amicus Therapeutics stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Amicus Therapeutics shares, starting with a $10,000 purchase of FOLD, presented on a split-history-adjusted basis factoring in the complete Amicus Therapeutics stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
04/29/2014 |
|
End date: |
04/25/2024 |
|
Start price/share: |
$2.22 |
|
End price/share: |
$10.17 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
358.11% |
|
Average Annual Total Return: |
16.44% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$45,797.40 |
|
Years: |
10.00 |
|
|
|
|
|